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Chronic diarrhoea is a frequent complaint in canine practice and the diagnostic path is often 
 characterised by numerous diagnostic tests and stepwise empirical treatments, often applied before 
gastrointestinal (GI) endoscopy/mucosal biopsies. These include dietary interventions (novel protein, 
hydrolysed protein diet), parasiticides and still, in many cases, antibacterials. Indiscriminate use of 
antibacterial drugs risks detrimental consequences for both the individual patient (antimicrobial 
resistance, long-term disruption of intestinal bacterial populations, potential worsening of GI signs) 
and general public. For that reason, in this Perspective essay we advocate use of antibacterials only 
after histopathologic evaluation of GI biopsies or, for those cases in which endoscopy is not possible, 
after other therapeutic trials, such as diet/pre-probiotics or anti-inflammatory drugs have proven 
unsuccessful. They should be reserved, after appropriate dietary trials, for those canine chronic diar-
rhoeic patients with signs of true primary infection (i.e. signs of systemic inflammatory response 
syndrome or evidence of adherent-invasive bacteria) that justify antibacterial use.
The standard diagnostic investigation of chronic diarrhoea usu-
ally includes a variety of laboratory investigations, such as com-
plete blood count, serum biochemistry panel, urinalysis, faecal 
exams, evaluation of pancreatic function and inflammation, 
endocrine assays (i.e. adrenal gland function), as well as diagnos-
tic imaging procedures (e.g. abdominal radiographs/ultrasound) 
and GI endoscopy, including mucosal biopsies for histopatho-
logical examination. Empirical treatment is often trialled and 
can include dietary interventions, parasiticides and antibacteri-
als (ABs) such as metronidazole or tylosin (Jergens et al. 2003, 
Kilpinen et al. 2015, Allenspach et al. 2016). These empirical 
treatments are often administered before GI endoscopy/muco-
sal biopsy because they may represent effective strategies for 
managing canine chronic enteropathy (Volkmann et al. 2017, 
Heilmann et al. 2018). Corticosteroids and other immunosup-
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are generally recommended after other treatment strategies have 
been exhausted and after mucosal biopsies have been obtained, 
which are necessary to diagnose intestinal inflammation and 
other GI disorders such as (primary) lymphangiectasia, infectious 
agents (e.g. fungal infections, adherent-invasive Escherichia coli) 
and neoplastic infiltration (e.g. lymphoma).
Antibiotic-responsive diarrhoea is recognised as one form of 
chronic enteropathy. Its clinical presentation is indistinguishable 
from other types of chronic enteropathy; it is associated with intes-
tinal microbiota dysbiosis (Hall 2011) and responds exquisitely 
well to administration of ABs, while it often recurs as soon as they 
are withdrawn (Hall 2011, Westermarck 2016). Most often, tylo-
sin (tylosin-responsive diarrhoea) (Westermarck et al. 2005), met-
ronidazole (Allenspach et al. 2016) and oxytetracycline (Hall 2011) 
have been used as therapy. Diagnosis is based on a positive response 
to ABs after exclusion of other conditions as outlined above. In 
antibiotic-responsive diarrhoea, histopathology of intestinal biop-
sies, if acquired, frequently shows no or only mild non-specific 
inflammatory infiltrates or abnormalities (Hall 2011, Volkmann 
et al. 2017). However, although ABs constitute an empirical ther-
apy instituted by many clinicians in dogs with chronic diarrhoea, 
this might lead to unnecessary administration or overuse of ABs, 
as not all of these dogs will eventually be diagnosed with antibi-
otic-responsive diarrhoea. This practice is of even greater concern 
considering recent reports in which antibiotic-responsive diarrhoea 
was retrospectively reported in only 11 of 136 (8%) (Volkmann 
et al. 2017) and 33 of 203 (16.2%) (Allenspach et al. 2016) of dogs 
with chronic diarrhoea, respectively. In addition, a study by Jergens 
et al. (2010) is noteworthy, because it shows oral prednisone alone 
to be clinically as effective as prednisone plus metronidazole in dogs 
suffering from inflammatory bowel disease, suggesting that the use 
of antibiotics might not always be necessary.
Based on our experience and on the evidence in the literature 
reported here, the aim of this report is to make a strong argument 
against the empirical use of ABs when routinely managing dogs 
with suspected chronic enteropathy. The use of ABs should be 
reserved for patients in which all other conditions are excluded 
and other empirical treatments have been exhausted. The follow-
ing paragraphs will elucidate potential detrimental effects of ABs 
on individual gut health and public health.
EFFECTS OF ANTIBACTERIALS ON GI 
MICROBIOTA
Although the effect of AB administration on the faecal microbiota 
still needs to be defined further, some aspects have been investigated 
in humans (Rizzatti et al. 2018) and both healthy and diseased ani-
mals. It is known that AB administration causes changes in the 
composition and richness of the intestinal microbiota in dogs and 
cats and that this dysbiosis can be detrimental to overall host health 
(Suchodolski 2016), similarly to those presenting with inflamma-
tory bowel disease (Minamoto et al. 2015). Specifically, the admin-
istration of oral tylosin (20 to 22 mg/kg SID for 14 days) to healthy 
dogs was associated with changes in the proportions of jejunal bac-
teria (e.g. increases in Enterococcus-like organisms and Pasteurella 
spp.). Microbiota alterations (i.e.  increase of Escherichia coli-like 
organisms) were still observed 14 days after withdrawal of tylosin 
(Suchodolski et al. 2009). The phylogenetic composition of the 
microbiota following tylosin withdrawal was comparable to day 0 
in only two of five dogs, while bacterial diversity was similar in three 
of five dogs, suggesting a possible long-term adverse effect in some 
animals (Suchodolski et al. 2009). Very recently, as found in healthy 
dogs, it was shown that the administration of tylosin (20 mg/kg PO 
BID) induced dysbiosis- and eubiosis was not restored by 56 days 
following tylosin discontinuation, leading the authors to conclude 
that in these patients “… reestablishment of the native microbiota is 
possible but not guaranteed.” (Manchester et al. 2019). Faecal bacte-
rial diversity was also reduced when administering oral metronida-
zole for 14 days (12.5 mg/kg BID) to healthy dogs (Igarashi et al. 
2014). Similarly, oral administration of amoxicillin (10 mg/kg BID 
for 7 days) to healthy dogs resulted in differences in faecal bacte-
rial composition before and after administration, with many faecal 
E. coli isolates showing increased resistance to multiple ABs during 
and after treatment (Grønvold et al. 2010). Interestingly, in dogs 
with tylosin-responsive diarrhoea, there were increases in faecal 
Enterococcus spp. and other potentially probiotic bacteria (includ-
ing lactic acid bacteria) (Kilpinen et al. 2015). It was speculated 
that there could be a possible indirect probiotic effect of tylosin 
by exerting a selection pressure, resulting in a relative increase in 
tylosin-resistant enterococci (Kilpinen et al. 2015). Although these 
results are interesting, there are still concerns that antibacterial 
resistance could be passed horizontally from commensal bacte-
ria or alleged probiotics to pathogenic bacteria sharing the same 
intestinal environment (von Wintersdorff et al. 2016).
Furthermore, the metabolic pathways through which ABs may 
alter gut homeostasis are still under investigation. For example, 
a recent paper suggests that the administration of a cocktail of 
antibiotics in mice (antibiotic-induced microbiome depletion) in 
addition to modifying the abundance of some bacterial species, 
also altered glucose homeostasis and luminal short-chain fatty 
acid concentration (enterocytes use glucose instead of butyrate, 
which is reduced in the intestinal lumen) and bile acid metabo-
lism (Zarrinpar et al. 2018).
Additionally, it is anecdotally reported that select antimi-
crobials may have immunomodulatory or anti-inflammatory 
actions in treating chronic enteropathy; in particular, metroni-
dazole has recognised immunosuppressive and anti-inflamma-
tory properties (Shakir et al. 2011). In one small pilot study, 
the effects of metronidazole, tylosin and conjugated linoleic 
acid on immune function were evaluated in healthy dogs (Jer-
gens et al. 2007). In this study, peripheral blood mononuclear 
cells were isolated, incubated with graded doses of the antibi-
otics and conjugated linoleic acid, and immune responses were 
investigated using MTT cytotoxicity assay, immunostaining and 
flow cytometry of B and T lymphocyte subpopulations and in 
vitro mitogen-induced lymphocyte proliferation (3H-thymidine 
incorporation). Results indicated that metronidazole and 
tylosin, at different dosages, were not successful in arresting 
mitogen-stimulated proliferation of lymphocytes; in contrast, 
conjugated linoleic acid was shown to directly inhibit peripheral 
blood mononuclear cell blastogenesis. Moreover, it must also be 
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remembered that the use of antimicrobials for non-antimicrobial 
effects is questionable and discouraged (Weese et al. 2015).
ANTIBACTERIAL RESISTANCE
Antibiotic resistance represents one of the most serious and 
imminent health-related problems worldwide (WHO 2017); 
the last joint EFSA/ECDC report Antimicrobial resistance in 
Europe, (http://www.efsa.europa.eu/it/interactive_pages/AMR_
Report_2016) based on 2016 data reflects on this alarming sit-
uation. The problem is also recognised in companion animals 
(Peter et al. 2017), with serious potential concerns for human 
health associated with methicillin-resistant Staphylococcus aureus 
(MRSA) (Rossi et al. 2017). More specifically, for complaints 
related to the digestive tract, the gut microbiota has been con-
sidered as a dynamic reservoir of antibiotic resistance, termed the 
(“gut resistome”), which can be affected by the administration 
of ABs (Rizzatti et al. 2018). A recent report showed that 54% 
of isolates of Clostridium perfringens from dogs with acute diar-
rhoea, which had not been treated with antibiotics, presented 
with a decreased susceptibility to metronidazole (Gobeli et al. 
2012). Moreover, dogs are also considered a possible reservoir 
of antibiotic resistant strains potentially dangerous for human 
patients. This includes the discovery of epidemic ribotypes of 
multiresistant Clostridioides (Clostridium) difficile (Nagy 2018) 
in dogs with GI disorders (Orden et al. 2017).
ALTERNATIVE INTESTINAL MICROBIOTA 
MODULATION
There is growing interest and clinical evidence supporting alter-
native treatments to modulate bacterial populations, which could 
include the administration of prebiotics, probiotics or synbiotics. 
Several studies show that probiotics are likely beneficial in cases 
of diarrhoea, even in dogs suffering from inflammatory bowel 
disease (Rossi et al. 2014, White et al. 2017, Rossi et al. 2018). 
Another promising modality is faecal microbiota transplantation. 
It has been recommended for recurrent Clostridioides (Clostrid-
ium) difficile infections in humans, a hospital-acquired infection 
that usually develops after extensive AB treatment (Cammarota 
FIG 1. Diagnostic algorithm for the diarrhoeic dog. This algorithm is suggested by our combined clinical experience, but different parts are also 
variably widely reported in literature, including (but not limited to): Jergens et al. 2003, Allenspach et al. 2007, Cerquetella et al. 2010, Washabau 
et al. 2010, Allenspach et al. 2016, Westermarck et al. Westermarck 2016, Erdmann & Heilmann 2017, Volkmann et al. 2017, Cerquetella et al. 
2018, Heilmann et al. 2018. It is recommended to use (targeted, not broad spectrum) ABs in the chronic diarrhoeic dog (when there is no clinical 
evidence of a medical rationale for their immediate use), only at the end of the diagnostic protocol, once GI biopsies are performed, and with evidence 
of infectious causes. *In some cases more than one diet change may be needed, and for this reason duration of diet trial may vary. §Depending on the 
severity of clinical condition, these trials can be postponed going forward with the algorithm. FRD Food-responsive diarrhoea, IBD Inflammatory bowel 
disease, SRD Immunosuppressive/steroid-responsive diarrhoea
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et al. 2015,Cammarota et al. 2017, Quraishi et al. 2017). Even 
though an equivalent of this condition is lacking in dogs (it is 
not comparable to an infection with Clostridioides [Clostridium] 
difficile sometimes seen in dogs with both acute and chronic diar-
rhoea) (Marks et al. 2011), it is reasonable to assume that dys-
biosis caused by inappropriate AB treatment should be avoided 
in canine patients. Results from faecal microbiota transplanta-
tion in human subjects suggest that the attempt to “restore” a 
physiological microbiota could be more effective than ABs alone 
in some specific cases (Cammarota et al. 2017, Quraishi et al. 
2017). Unfortunately, large scale studies on the clinical effect 
(short- and long-term effects) or the efficacy of restoring eubi-
osis by administration of faecal microbiota transplantation are 
currently lacking. The optimal donor screening and indication, 
as well as the best modality and frequency of administration of 
faecal microbiota transplantation in dogs, is currently unknown, 
because only a few studies are available (Chaitman et al. 2016, 
Burton et  al. 2016, Pereira et  al. 2018). We are still a far way 
away from suggesting its use as a routine treatment in dogs with 
acute and/or chronic diarrhoea, because scientific evidence from 
appropriately designed prospective studies is lacking. However, 
these data underline that ABs may not be the best option to treat 
some forms of infectious diarrhoea; on the contrary, alternative 
attempts to modulate and restore intestinal microbiota should be 
considered in diarrhoeic dogs.
PROPOSAL FOR RATIONAL USE OF 
ANTIBACTERIALS IN THE DIAGNOSIS AND 
TREATMENT OF CHRONIC DIARRHOEA IN DOGS
The necessity of avoiding empirical and injudicious use of anti-
bacterials in diarrhoeic dogs has previously been emphasised 
(Marks et al. 2011, Heilmann et al. 2018). Furthermore, con-
sidering the global concern for rising antibiotic resistance, the 
dysbiosis associated with indiscriminate use of ABs, and the 
potentially associated worsening of GI signs, the risks for both 
the individual patient and potential harm to the general public 
of using ABs in chronic GI diseases needs to be fully appreciated 
by clinicians.
Clinicians should consider using ABs only after appropriate 
dietary trials have been unsuccessful and only after histopatho-
logic evaluation of GI biopsies in all cases in which it is possible. 
In cases in which biopsies cannot be acquired we recommend 
use of ABs only after other empirical therapeutic trials are unsuc-
cessful. In short, after having excluded all conditions (Fig 1) that 
would not benefit from administration of ABs, they can be con-
sidered for those canine chronic diarrhoeic patients with signs of 
true primary infection that justify AB usage or in those patients 
in which endoscopy is not possible (or histopathology is not con-
clusive) and that are not responsive to any other treatment. They 
may be an option in those cases showing signs of systemic inflam-
matory response syndrome (e.g. pyrexia, inflammatory left-
shifted leucogram or leucopenia) or in cases of acute infection 
with a known enteric bacterial pathogen that is not self-limiting 
or responding to symptomatic treatment. However, considering 
that there are few indications for using ABs in chronic diarrhoea, 
because primary bacterial agents causing non-self-limiting dis-
ease are rare (Marks et al. 2011), it means that these treatments 
should be reserved for specific diseases and in accordance with 
appropriate AB resistance testing panels, avoiding the empirical 
use of broad spectrum ABs such as amoxicillin/clavulanic acid or 
fluoroquinolones.
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